research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-10 and is reviewed periodically as new material appears.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
This recommendation by the INCB has been criticized as an attempt by the Board to overstep its legitimate mandate and as establishing a reason for governments to violate the human rights (i.e., religious freedom) of ceremonial ayahuasca drinkers. Under American federal law, DMT is a Schedule I drug that is illegal to possess or consume; however, certain religious groups have been legally permitted to consume ayahuasca. A court case allowing the União do Vegetal to import and use the tea for religious purposes in the United States, Gonzales v. O Centro Espírita Beneficente União do Vegetal, was heard by the U.S. Supreme Court on November 1, 2005; the decision, released February 21, 2006, allows the UDV to use the tea in its ceremonies pursuant to the Religious Freedom Restoration Act. In a similar case in Ashland, Oregon-based Santo Daime church sued for their right to import and consume ayahuasca tea. In March 2009, U.S. District Court Judge Panner ruled in favor of the Santo Daime, acknowledging its protection from prosecution under the Religious Freedom Restoration Act. In 2017 the Santo Daime Church Céu do Montréal in Canada received religious exemption to use ayahuasca as a sacrament in their rituals. Religious use in Brazil was legalized after two official inquiries into the tea in the mid-1980s, which concluded that ayahuasca is not a recreational drug and has valid spiritual uses.
=== Soup mixes === Lipton ran an advertisement campaign promoting French onion dip prepared at home using Lipton's French onion soup mix, thus helping to popularize chips and dip. Hundreds of new commercially produced varieties of dips were later introduced in the U.S.
ArH + CH2O → ArCH2OH When conducted in the presence of hydrogen chloride, the product is the chloromethyl compound, as described in the Blanc chloromethylation. If the arene is electron-rich, as in phenols, elaborate condensations ensue. With 4-substituted phenols one obtains calixarenes. Phenol results in polymers.
Sources: en.wikipedia.org
Trump signs an executive order directing DHS to create voter lists and USPS to mail ballots only to people on the list. A federal judge rules that Trump's Executive Order 14290 barring federal funding for NPR and PBS violates the First Amendment. The U.S. Supreme Court rules 8–1 that talk therapy used in conversion therapy is protected speech under the First Amendment and orders lower courts to apply strict scrutiny to a Colorado law banning conversion therapy on minors. This ruling potentially strikes down existing restrictions on conversion therapy in the U.S.
No chromosome translocations, chimeric genes, or fusion proteins have been described in BIA-ALCL although the neoplastic cells in the disease have been described to have gene copy number variations involving gains in gene copies on the p arm of chromosome 19 and losses of gene copies in the p arms of chromosome 10 and 1. The neoplastic cells in BIA-ALCL show mutations of the STAT3 gene in 64% of cases and reports of mutations in JAK1, JAK3, DNMT3A, and TP53 genes. The development of BIA-ALCL, it has often been suggested, may be at least in part a T-cell-induced, inflammation-driven cancer response to the implant.
When genotypes grown together in a diverse population have different profiles of resource use they complement each other in the exploitation of the limiting resource and therefore are subject to smaller between-plant competition. In case of disease or environmental change some plants will take over when others fail. Yield stability over years and environments can be better than pure lines due to compensation. Participatory plant breeding (PPB) methods represent alternatives aimed to improve local adaptation breeding, to promote genetic diversity, to empower farmers and rural communities. In PPB farmers are actively participating in developing new cultivars or populations, e.g. by performing selection.
Some groups of people have specialized transfusion requirements. Fetuses, very low-birth-weight infants, and immunocompromised people are at risk for developing severe infection with cytomegalovirus (CMV)―an opportunistic pathogen for which approximately 50% of blood donors test positive―and may be transfused with CMV-negative blood to prevent infection. Those who are at risk of developing graft-versus-host disease, such as bone marrow transplant recipients, receive blood that has been irradiated to inactivate the T lymphocytes that are responsible for this reaction. People who have had serious allergic reactions to blood transfusions in the past may be transfused with blood that has been "washed" to remove plasma. The history of the patient is also examined to see if they have previously identified antibodies and any other serological anomalies. A direct antiglobulin test (Coombs test) is also performed as part of the antibody investigation. Donor blood is generally screened for transfusion-transmitted infections such as HIV. As of 2018, the World Health Organization reported that nearly 100% of blood donations in high- and upper-middle-income countries underwent infectious disease screening, but the figures for lower-middle-income and low-income countries were 82% and 80.3% respectively.
Sources: en.wikipedia.org
Hazard research is published: a study indicates common food allergies are not benign but are associated with increased risk of cardiovascular mortality (9 Nov), in a commentary, scientists warn that to "reduce plastic pollution efficiently and economically, policy should prioritize regulating and reducing upstream production rather than downstream pollution cleanup" as "popularized by The Ocean Cleanup" (9 Nov), social unconnectedness confirmed as likely substantial mortality risk factor using UK Biobank data (10 Nov), nanoplastic pollution and consumption identified as a likely Parkinson's disease risk factor (17 Nov), a review cautions "robust evidence has yet to emerge that [air treatment technologies] are effective at reducing respiratory or gastrointestinal infections in real world settings" (20 Nov), a content analysis of packaging marketing of infant and toddler foods in supermarkets suggests protection of young children's diets from harmful influence of food marketing is needed (28 Nov), a preprint suggests some large language models have an 'extractable memorization' flaw by which training data can be extracted at affordable costs by queries (28 Nov).
===== Laurasiatheria ===== Order Artiodactyla (even-toed ungulates) Family Antilocapridae Antilocapra americana, pronghorn (2019) Family Balaenidae Balaena mysticetus, bowhead whale (2015) Eubalaena glacialis, North Atlantic right whale (2018) Family Balaenopteridae Balaenoptera acutorostrata, common minke whale (2014) Balaenoptera borealis, sei whale (2018) Balaenoptera musculus, blue whale (2018) Balaenoptera physalus, fin whale (2014) Megaptera novaeangliae, humpback whale (2018) Family Bovidae Ammotragus lervia, Barbary sheep (2019) Antidorcas marsupialis, Springbox (2019) Bison bonasus, European bison (2017) Bos grunniens, yak 2012 () Bos primigenius indicus, zebu or Brahman cattle (2012) Bos primigenius taurus, cow 2009 () Bubalus bubalis, river buffalo (2017) Budorcas taxicolor, Takin (2023) Capra ibex, Goats (2019) Cephalophus harveyi, Harvey's duiker (2019) Connochaetes taurinus, blue wildebeest (2019) Damaliscus lunatus, common tsessebe (2019) Gazella thomsoni, Thomson's gazelle (2019) Hippotragus niger, Sable Antelope (2019) Kobus ellipsiprymnus, Waterbuck (2019) Litocranius walleri, Gerenuk (2019) Oreotragus oreotragus, Klipspringer (2019) Oryx gazella, Gemsbok (2019) Ourebia ourebi, Oribi (2019) Ovis ammon, Argali (2019) Ovis ammon polii, marco polo sheep (2017) Nanger granti, Grant's gazelle (2019) Neotragus moschatus, Suni (2019) Neotragus pygmaeus, Royal antelope (2019) Philantomba maxwellii, Maxwell's duiker (2019) Procapra przewalskii, Przewalski's gazelle (2019) Pseudois nayaur, Bharal (2019) Pseudoryx nghetinhensis, Saola (2025) Raphicerus campestris, Steenbox (2019) Redunca redunca, Bohor reedbuck (2019) Syncerus caffer, African buffalo (2019) Sylvicapra grimmia, common duiker (2019) Tragelaphus, Spiral-horned bovine (2019) Tragelaphus buxtoni, Mountain nyala (2019) Tragelaphus strepsiceros, Greater kudu (2019) Tragelaphus imberbis, Lesser kudu (2019) Tragelaphus spekii, Sitatunga (2019) Tragelaphus scriptus, Bushbuck (2019) Taurotragus oryx, Common eland (2019) Family Camelidae Camelus ferus, Wild Bactrian camel (2007) Family Cervidae Cervus albirostris, Tharold's deer (2019) Elaphurus davidianus, Père David's deer (2018) Muntiacus crinifrons, hairy-fronted muntjac (2019) Muntiacus muntjak, Indian muntjac (2019) Muntiacus reevesi, Reeves's muntjac (2019) Odocoileus hemionus, mule deer (2021) Rangifer tarandus, Reindeer (2017) Rusa alfredi, Visayan spotted deer (2025) Family Delphinidae Tursiops truncatus, bottlenosed dolphin (2012) Neophocaena phocaenoides, finless porpoise (2014) Orcinus orca, killer whale (2015) Sousa chinensis, Indo-Pacific humpback dolphin (2019) Family Eschrichtiidae Eschrichtius robustus, gray whale (2018) Family Giraffidae Giraffa camelopardalis, Giraffe (2019) Giraffa camelopardalis tippelskirchi, Masai giraffe (2019) Okapia johnstoni, Okapi (2019) Family Monodontidae Delphinapterus, beluga whale (2017) Family Moschidae Moschus berezovskii, forest musk deer (2018) Moschus chrysogaster, Alpine musk deer (2019) Family Phocoenidae Neophocaena asiaeorientalis sunameri, East Asian finless porpoise (2024) Neophocaena asiaorientalis asiaorientalis, Yangtze finless porpoise (2024) Family Physeteridae Physeter macrocephalus, sperm whale (2019) Family Suidae Sus scrofa, pig (2012) Family Tragulidae Tragulus javanicus, Java mouse-deer (2019) Order Carnivora Family Felidae Acinonyx jubatus, cheetah (2015) Felis catus, cat (2007) Panthera leo, lion (2013) Panthera pardus, Amur leopard (2016) Panthera tigris tigris, Siberian tiger (2013) Panthera tigris tigris, Bengal tiger (2013) Panthera uncia, snow leopard (2013) Prionailurus bengalensis, leopard cat (2016) Family Canidae Canis familiaris, dog (2005) Canis lupus lupus, wolf (2017). Lycaon pictus, african wild dog (2018) Family Ursidae Ailuropoda melanoleuca, giant panda (2010) Ursus arctos ssp. horribilis, Grizzly bear (2018) Ursus americanus, American black bear (2019) Ursus maritimus, Polar bear (2014) Family Odobenidae Odobenus rosmarus, walrus (2015) Family Phocidae Pusa sibirica, Baikal seal (2024) Pusa caspica, Caspian seal (2024) Phoca vitulina, Harbor seal (2024) Pusa hispida, Ringed seal (2024) Family Mustelidae Enhydra lutris kenyoni, sea otter (2017) Mustela erminea, stoat (2018) Mustela furo, ferret (2014) Pteronura brasiliensis, giant otter (2019) Order Chiroptera Family Megadermatidae Megaderma lyra, greater false vampire bat (2013) Family Mormoopidae Pteronotus parnellii, Parnell's mustached bat (2013) Family Pteropodidae Pteropus vampyrus, fruit bat (2012) Eidolon helvum, Old World fruit bat (2013) Family Rhinolophidae Rhinolophus ferrumequinum, greater horseshoe bat (2013) Family Vespertilionidae Myotis lucifugus, little brown bat (2010) Myotis mystacinus, whiskered bat (2024) Family Phyllostomidae Leptonycteris yerbabuenae, long nosed bat (2020) Leptonycteris nivalis, greater long nosed bat (2020) Musonycteris harrisoni, banana bat (2020) Artibeus jamaicensis, Jamaican fruit bat (2020) Macrotus waterhousii, Waterhouse's leaf-nosed bat (2020 Order Erinaceomorpha, Family Erinaceidae Erinaceus europaeus, western European hedgehog () Order Eulipotyphla, Family Solenodontidae Solenodon parodoxus, Hispaniolan solenodon (2018) Order Perissodactyla (odd-toed ungulates) Family Equidae Equus caballus, horse (2009 2018)
Laboratory Test Request and Sample Receiving Test Preparation, LIMS Processing, Test Results Recording and Verification Report Preparation and Distribution Laboratory Test Scheduling Prescheduled Testing Specimen and Sample Tracking/Chain of Custody Media, Reagents, Controls: Manufacturing and Inventory Interoperability and Data Exchange Statistical Analysis and Surveillance Billing for Laboratory Services Contract and Grant Management Training, Education and Resource Management Laboratory Certifications/Licensing Customer Relationship Management Quality Control (QC) and Quality Assurance (QA) Management Laboratory Safety and Accident Investigation Laboratory Mutual Assistance/Disaster Recovery Core IT Service Management: Hardware, Software and Services Policies and Procedures, including Budgeting and Funding
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.